Acrivon Therapeutics, Inc.
ACRV
$2.06
-$0.04-1.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.66% | -0.30% | -4.12% | 13.20% | -6.74% |
| Total Depreciation and Amortization | 5.74% | 6.09% | 3.44% | 4.18% | 7.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.45% | -24.99% | -15.72% | 3.17% | 8.97% |
| Change in Net Operating Assets | 103.25% | -4,439.39% | -106.75% | 2,719.23% | 101.35% |
| Cash from Operations | 27.64% | -34.79% | -24.05% | 26.05% | 14.97% |
| Capital Expenditure | -521.43% | 93.61% | 75.64% | -82.35% | -750.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.41% | -39.56% | 219.28% | -65.85% | 3.49% |
| Cash from Investing | 13.86% | -39.01% | 264.13% | -69.61% | 1.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -3.03% | 82.81% | -64.10% | -20.62% | 71.80% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 22,127.27% | 82.81% | -64.10% | -20.62% | 71.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 198.79% | -222.13% | 193.93% | -336.48% | 513.25% |